Table 1.
Relationships between expression of VEGFR-2, PDGFR-β, and C-met and clinicopathological factors
| Parameters | N |
VEGFR-2 |
P |
PDGFR-β |
P |
C-MET |
P | |||
|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | High | Low | High | Low | |||||
| N(%) |
93 |
80(86.0) |
13 |
|
18(19.4) |
75 |
|
75(80.6) |
18 |
|
|
Gender |
|
|
|
|
|
|
|
|
|
|
| Male |
77 |
69(89.6) |
8 |
|
15(19.5) |
62 |
|
61(79.2) |
16 |
|
| Female |
16 |
11(68.8) |
5 |
0.044 |
3(18.8) |
13 |
0.627 |
14(87.5) |
2 |
0.355 |
|
Age |
|
|
|
|
|
|
|
|
|
|
| ≤50 |
31 |
26(83.9) |
5 |
|
6(19.4) |
25 |
|
25(80.6) |
6 |
|
| >50 |
62 |
54(87.1) |
8 |
0.448 |
12(19.4) |
50 |
0.602 |
50(80.6) |
12 |
0.616 |
|
HBsAg |
|
|
|
|
|
|
|
|
|
|
| Positive |
79 |
71(89.9) |
8 |
|
16(20.3) |
63 |
|
63(79.7) |
16 |
|
| Negative |
14 |
9(64.3) |
5 |
0.024 |
2(14.3) |
12 |
0.461 |
12(85.7) |
2 |
0.461 |
|
AFP(IU/ML) |
|
|
|
|
|
|
|
|
|
|
| ≤400 |
47 |
39(83.0) |
8 |
|
5(10.6) |
42 |
|
39(83.0) |
8 |
|
| >400 |
46 |
41(89.1) |
5 |
0.290 |
13(28.3) |
33 |
0.029 |
36(78.3) |
10 |
0.377 |
|
Tumor number |
|
|
|
|
|
|
|
|
|
|
| Single |
29 |
26(89.7) |
3 |
|
2(6.9) |
27 |
|
23(79.3) |
6 |
|
| >1 |
64 |
54(84.4) |
10 |
0.371 |
16(25.0) |
48 |
0.033 |
52(81.3) |
12 |
0.516 |
|
Tumor size(cm) |
|
|
|
|
|
|
|
|
|
|
| ≤5 |
16 |
13(81.3) |
3 |
|
4(25.0) |
12 |
|
13(81.3) |
3 |
|
| >5 |
77 |
67(87.0) |
10 |
0.394 |
14(18.2) |
63 |
0.373 |
62(80.5) |
15 |
0.627 |
| Differentiation |
|
|
|
|
|
|
|
|
|
|
| High |
26 |
26(100) |
0 |
|
7(26.9) |
19 |
|
21(80.8) |
5 |
|
| Middle |
45 |
38(84.4) |
7 |
|
6(13.3) |
39 |
|
35(77.8) |
10 |
|
| Low |
22 |
16(72.7) |
6 |
0.023 |
5(22.7) |
17 |
0.340 |
19(86.4) |
3 |
0.705 |
|
Child-Pugh |
|
|
|
|
|
|
|
|
|
|
| A |
82 |
70(85.4) |
12 |
|
14(17.1) |
68 |
|
64(78.0) |
18 |
|
| B |
11 |
10(90.9) |
1 |
0.523 |
4(36.4) |
7 |
0.134 |
11(100) |
0 |
0.080 |
|
BCLC |
|
|
|
|
|
|
|
|
|
|
| B |
20 |
15(75.0) |
5 |
|
2(10.0) |
18 |
|
13(65.0) |
7 |
|
| C |
73 |
65(89.0) |
8 |
0.111 |
16(21.9) |
57 |
0.194 |
62(84.9) |
11 |
0.051 |
|
Hepatic cirrhosis |
|
|
|
|
|
|
|
|
|
|
| Yes |
48 |
45(93.8) |
3 |
|
5(10.4) |
43 |
|
37(77.1) |
11 |
|
| No |
45 |
35(77.8) |
10 |
0.026 |
13(28.9) |
32 |
0.023 |
38(84.4) |
7 |
0.263 |
| Ascites |
|
|
|
|
|
|
|
|
|
|
| Yes |
19 |
17(89.5) |
2 |
|
3(15.8) |
16 |
|
17(89.5) |
2 |
|
| No |
74 |
63(85.1) |
11 |
0.476 |
15(20.3) |
59 |
0.470 |
58(78.4) |
16 |
0.228 |
| Tumor thrombus |
|
|
|
|
|
|
|
|
|
|
| Yes |
38 |
33(86.8) |
5 |
|
10(26.3) |
28 |
|
34(89.5) |
4 |
|
| No |
55 |
47(85.5) |
8 |
0.551 |
8(14.5) |
47( |
0.126 |
41(74.5) |
14 |
0.061 |
|
Extrahepatic metastasis |
|
|
|
|
|
|
|
|
|
|
| Yes |
48 |
43(89.6) |
5 |
|
8(16.7) |
40 |
|
40(83.3) |
8 |
|
| No | 45 | 37(82.2) | 8 | 0.235 | 10(22.2) | 35 | 0.339 | 35(77.8) | 10 | 0.339 |
VEGFR-2, vascular endothelial growth factor receptor-2; PDGFR-β, platelet-derived growth factor receptor-β; C-MET, hepatocyte growth factor receptor; HbsAg, hepatitis B surface antigen; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage.